Imaging of pediatric liver tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper

Gary R Schooler1, Juan C Infante2, Michael Acord3

  • 1Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Pediatric Blood & Cancer
|September 14, 2022
PubMed

Insights

Pediatric primary liver cancer is rare. This paper offers expert imaging guidelines for diagnosing and monitoring childhood liver tumors like hepatoblastoma and hepatocellular carcinoma.

Area of Science:

  • Pediatric Oncology
  • Medical Imaging
  • Hepatobiliary Diseases

Background:

  • Primary hepatic malignancies are uncommon in children, representing 1-2% of all pediatric neoplasms.
  • Hepatoblastoma and hepatocellular carcinoma are the predominant types in young children and older children, respectively.
  • Standardized imaging protocols are crucial for accurate diagnosis and treatment assessment.

Purpose of the Study:

  • To establish consensus-based imaging recommendations for primary hepatic malignancies in pediatric patients.
  • To guide the evaluation of these rare tumors at initial diagnosis.
  • To provide a framework for follow-up imaging during and after therapy.

Main Methods:

  • A panel of pediatric oncologists and radiologists convened to develop guidelines.
  • Recommendations were based on a review of current literature and clinical expertise.
  • Consensus was reached through a structured Delphi-like process.

Main Results:

  • Detailed imaging recommendations for diagnosis, including modality choices and sequences.
  • Specific guidance for surveillance and response assessment during and after treatment.
  • Emphasis on multi-disciplinary team collaboration for optimal patient management.

Conclusions:

  • Standardized imaging is essential for the effective management of pediatric primary liver cancer.
  • These consensus guidelines aim to improve diagnostic accuracy and treatment monitoring.
  • Adherence to these recommendations can enhance outcomes for children with liver malignancies.